GTS Securities’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

GTS Securities’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-318,500	Closed	-$31.5M	–	4190
2024 Q3	$31.5M	Buy	318,500 +103,100	+48%	+$10.1M	0.07%	170
2024 Q2	$20M	Sell	215,400 -322,900	-60%	-$29M	0.04%	258
2024 Q1	$51.1M	Sell	538,300 -228,500	-30%	-$21.2M	0.09%	102
2023 Q4	$68.5M	Buy	766,800 +400,100	+109%	+$29.7M	0.12%	80
2023 Q3	$26.8M	Buy	+366,700	New	+$29.3M	0.05%	242

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GTS Securities's XBI Position: Q1 2026 in Review

GTS Securities reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 73% in Q1 2026, selling an estimated $8.48M and leaving 25,120 shares worth $3.21M. The position accounts for 0.11% of the portfolio, ranked #122.

GTS Securities first reported a position in XBI in Q3 2023 and has held it in 11 quarters since. The position peaked at $11.3M in Q4 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

GTS Securities held 25,120 shares of State Street SPDR S&P Biotech ETF worth $3.21M as of Q1 2026.
GTS Securities sold 67,958 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $8.48M.
State Street SPDR S&P Biotech ETF made up 0.11% of GTS Securities's portfolio in Q1 2026, its #122 holding.
GTS Securities first reported a position in State Street SPDR S&P Biotech ETF in Q3 2023 and has held it in 11 quarters since.
GTS Securities's State Street SPDR S&P Biotech ETF position peaked at $11.3M in Q4 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.